Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 6. Pathway analysis of CMLD

Published byIsaac Conley Modified over 6 years ago

Similar presentations

Presentation on theme: "Fig. 6. Pathway analysis of CMLD"— Presentation transcript:

1 Fig. 6. Pathway analysis of CMLD010509.
Pathway analysis of CMLD (A) Network enrichment analysis of 54 depleted proteins with more than twofold change analyzed in the KEGG database, showing that cancer pathways were highly enriched among these depleted proteins. AML, acute myeloid leukemia; CML, chronic myeloid leukemia; MAPK, mitogen-activated protein kinase; JAK/STAT, Janus kinase/signal transducer and activator of transcription. (B) The 54 depleted proteins were queried against MSigDB C2 canonical pathway database, showing an enrichment of MM specific oncoproteins including IRF4 pathway. (C) Z scores of the 54 proteins evaluated on 1000 cell lines of the CCLE database. (D) Z scores of the 54 proteins evaluated on two independent gene expression profiles including patients at diagnosis (GSE16558) and at relapse (GSE6477). Salomon Manier et al., Sci Transl Med 2017;9:eaal2668 Published by AAAS

Download ppt "Fig. 6. Pathway analysis of CMLD"

Similar presentations

Finding Cancer Genes.

Finding Cancer Genes.
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia by Michael Kalos, Bruce.

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia by Michael Kalos, Bruce.
Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.
Fig. 3. Effect of tolfenamic acid (TA) on the MAPK pathway in nasopharyngeal cancer cells. (A) Immunoblot of TA-treated cells stained with antibodies against.

Fig. 3. Effect of tolfenamic acid (TA) on the MAPK pathway in nasopharyngeal cancer cells. (A) Immunoblot of TA-treated cells stained with antibodies against.
Molecular consequences of chromosomal rearrangements that modify the AML1/CBFβ transcription factor complex, the most frequent target of reciprocal translocations.

Molecular consequences of chromosomal rearrangements that modify the AML1/CBFβ transcription factor complex, the most frequent target of reciprocal translocations.
Fig. 1. TP is highly expressed in myeloma.

Fig. 1. TP is highly expressed in myeloma.
Fig. 8. Recurrent copy number amplification of BRD4 gene was observed across common cancers. Recurrent copy number amplification of BRD4 gene was observed.

Fig. 8. Recurrent copy number amplification of BRD4 gene was observed across common cancers. Recurrent copy number amplification of BRD4 gene was observed.
Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.

Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.
Fig. 7. Gradient of adipocyte size and FAI around the human coronaries in the presence or absence of coronary atherosclerosis. Gradient of adipocyte size.

Fig. 7. Gradient of adipocyte size and FAI around the human coronaries in the presence or absence of coronary atherosclerosis. Gradient of adipocyte size.
Luis A. Carvajal, Ulrich Steidl  Cell Stem Cell 

Luis A. Carvajal, Ulrich Steidl  Cell Stem Cell 
Fig. 3. Copy number loss as a potential resistance mechanism in an independent cohort. Copy number loss as a potential resistance mechanism in an independent.

Fig. 3. Copy number loss as a potential resistance mechanism in an independent cohort. Copy number loss as a potential resistance mechanism in an independent.
Differentiation of AZD4785 from MAPK pathway inhibitors in vitro

Differentiation of AZD4785 from MAPK pathway inhibitors in vitro
Fig. 6. dAST directly from clinical samples using dPCR and dLAMP for quantification. dAST directly from clinical samples using dPCR and dLAMP for quantification.

Fig. 6. dAST directly from clinical samples using dPCR and dLAMP for quantification. dAST directly from clinical samples using dPCR and dLAMP for quantification.
Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.

Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.
Altered microRNA expression in stenoses of native arteriovenous fistulas in hemodialysis patients  Lei Lv, MD, Weibin Huang, MD, Jiwei Zhang, MD, Yaxue.

Altered microRNA expression in stenoses of native arteriovenous fistulas in hemodialysis patients  Lei Lv, MD, Weibin Huang, MD, Jiwei Zhang, MD, Yaxue.
Fig. 4. BET bromodomain inhibition suppresses transactivation of shared transcriptional networks across HF models. BET bromodomain inhibition suppresses.

Fig. 4. BET bromodomain inhibition suppresses transactivation of shared transcriptional networks across HF models. BET bromodomain inhibition suppresses.
Fig. 3. Cytokines trigger proliferation and block differentiation of perivascular adipocytes. Cytokines trigger proliferation and block differentiation.

Fig. 3. Cytokines trigger proliferation and block differentiation of perivascular adipocytes. Cytokines trigger proliferation and block differentiation.
Fig. 1. The cell-intrinsic fibroblast circadian proteome contains numerous cytoskeletal regulators. The cell-intrinsic fibroblast circadian proteome contains.

Fig. 1. The cell-intrinsic fibroblast circadian proteome contains numerous cytoskeletal regulators. The cell-intrinsic fibroblast circadian proteome contains.
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
Fig. 5. Circulating PPi concentration does not correlate with severity of calcification phenotype in mice. Circulating PPi concentration does not correlate.

Fig. 5. Circulating PPi concentration does not correlate with severity of calcification phenotype in mice. Circulating PPi concentration does not correlate.

Similar presentations

Ads by Google